Catalent's GPEx technology creates stable, high-yielding mammalian cell lines

Apr 12, 2013
By PharmTech Editors

Catalent’s proprietary GPEx® technology creates stable, high-yielding mammalian cell lines with high speed and efficiency, getting customer’s drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production.

GPEx technology uses a retrovector technology that ensures the stable transduction of targeted cells, approaching 100% efficiency. This level of efficiency eliminates the requirement for selectable markers and stable clonal cell lines are produced in less than five months for any mammalian cell line or in-house Master.